Induction of drug metabolism: species differences and toxicological relevance.

[1]  M. Boroujerdi,et al.  Biotransformation of Xenobiotics , 2015 .

[2]  Q. Ma.  Xenobiotic-activated receptors: from transcription to drug metabolism to disease. , 2008, Chemical research in toxicology.

[3]  M. Negishi,et al.  Chapter 13:Receptor-Mediated Regulation of Cytochromes P450 , 2008 .

[4]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[5]  K. Yoshizato,et al.  Chimeric mice with humanized liver. , 2008, Toxicology.

[6]  N. Hewitt,et al.  Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  Nicola J Hewitt,et al.  Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations? , 2007, Chemico-biological interactions.

[8]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[9]  J. Idle,et al.  The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A , 2007, Drug Metabolism and Disposition.

[10]  V. Pustylnyak,et al.  Comparative study of CYP2B induction in the liver of rats and mice by different compounds. , 2007, Life sciences.

[11]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[12]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[13]  T. Maurer,et al.  Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction , 2006, Drug Metabolism and Disposition.

[14]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[15]  W. Krol,et al.  Cloning, tissue expression, and regulation of beagle dog CYP4A genes. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Jiunn H. Lin,et al.  CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications , 2006, Pharmaceutical Research.

[17]  J. Ward,et al.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. , 2006, Carcinogenesis.

[18]  M. Negishi,et al.  Nuclear receptors CAR and PXR in the regulation of hepatic metabolism , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .

[20]  D. Moore,et al.  Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.

[21]  A. Y. Lu,et al.  METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION? , 2005, Drug Metabolism and Disposition.

[22]  M. Dickins.  Induction of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[23]  R. Maronpot,et al.  The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.

[24]  K. Carroll,et al.  The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. , 2004, Toxicology and applied pharmacology.

[25]  J. Pascussi,et al.  Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  I. Rusyn,et al.  Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis , 2004 .

[27]  J. Ward,et al.  Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.

[28]  J. Lasker,et al.  Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  D. Barrett,et al.  Molecular analysis of peroxisome proliferation in the hamster. , 2004, Toxicology and applied pharmacology.

[30]  J. Bucher,et al.  Evaluating the human relevance of chemically induced animal tumors. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  J. Sahi,et al.  Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  F. Staedtler,et al.  Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. , 2003, Toxicology and applied pharmacology.

[33]  Hongbing Wang,et al.  Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[34]  J. Tredger,et al.  Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[35]  L. Moore,et al.  Functional and structural comparison of PXR and CAR. , 2003, Biochimica et biophysica acta.

[36]  James E Klaunig,et al.  The Human Relevance of Information on Carcinogenic Modes of Action: Overview , 2003, Critical reviews in toxicology.

[37]  Jennifer Seed,et al.  A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.

[38]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[39]  S. Kliewer,et al.  Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.

[40]  Sean Kim,et al.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[41]  H. Kikuchi.  [Regulation of cytochrome P-450 (CYP) genes by nuclear receptors]. , 2002, Nihon eiseigaku zasshi. Japanese journal of hygiene.

[42]  N. Plant,et al.  Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[43]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  J. Pascussi,et al.  Induction of CYP2C genes in human hepatocytes in primary culture. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[45]  D. Moore,et al.  The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism , 2000, Nature.

[46]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[47]  M. Negishi,et al.  Regulation of cytochrome P450 (CYP) genes by nuclear receptors. , 2000, The Biochemical journal.

[48]  R. J. Price,et al.  Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig. , 2000, Mutation research.

[49]  A. Li,et al.  2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. , 2000, Chemico-biological interactions.

[50]  S Coecke,et al.  The use of Long-term Hepatocyte Cultures for Detecting Induction of Drug Metabolising Enzymes: The Current Status , 1999, Alternatives to laboratory animals : ATLA.

[51]  B. Lake,et al.  A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. , 1999, Regulatory toxicology and pharmacology : RTP.

[52]  R. Roberts,et al.  The perturbation of apoptosis and mitosis by drugs and xenobiotics. , 1999, Pharmacology & therapeutics.

[53]  T Hashimoto,et al.  Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. , 1998, Carcinogenesis.

[54]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[55]  T. Crisp,et al.  Risk assessment of thyroid follicular cell tumors. , 1998, Environmental health perspectives.

[56]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[57]  E. Hodgson,et al.  Regulation of hepatic CYP1A isozymes by piperonyl butoxide and acenaphthylene in the mouse. , 1997, Chemico-biological interactions.

[58]  R A Goldbohm,et al.  A review of mechanisms underlying anticarcinogenicity by brassica vegetables. , 1997, Chemico-biological interactions.

[59]  C. Ioannides.  Cytochromes P450 Metabolic and Toxicological Aspects , 1996 .

[60]  P. Maurel.  The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man , 1996 .

[61]  F. Gonzalez,et al.  Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. , 1996, Molecular pharmacology.

[62]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[63]  J. Olsen,et al.  Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. , 1995, Cancer research.

[64]  P Grasso,et al.  Hepatic peroxisome proliferation in rodents and its significance for humans. , 1993, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[65]  I. White,et al.  Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. , 1993, Biochemical pharmacology.

[66]  T. Sugimura,et al.  Species Difference among Experimental Rodents in Induction of P450IA Family Enzymes by 2‐Amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine , 1992, Japanese journal of cancer research : Gann.

[67]  J. Huff,et al.  Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. , 1991, Environmental health perspectives.

[68]  P. Grasso,et al.  Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. , 1991, Mutation research.

[69]  P. Curran,et al.  The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. , 1991, Endocrine reviews.

[70]  R. Schulte‐Hermann,et al.  Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. , 1991, Cancer research.

[71]  B. Lake,et al.  Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. , 1989, Toxicology and applied pharmacology.

[72]  J. Olsen,et al.  Cancer among epileptic patients exposed to anticonvulsant drugs. , 1989, Journal of the National Cancer Institute.

[73]  A. Conney.  Induction of microsomal cytochrome P-450 enzymes: the first Bernard B. Brodie lecture at Pennsylvania State University. , 1986, Life sciences.

[74]  T. Orton,et al.  Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). , 1982, The Biochemical journal.

[75]  John Doull,et al.  Casarett and Doull's toxicology : the basic science of poisons , 2001 .

[76]  U. Pitkänen,et al.  Liver size and indices of drug metabolism in epileptics. , 1978, British journal of clinical pharmacology.

[77]  A. Conney.  Pharmacological implications of microsomal enzyme induction. , 1967, Pharmacological reviews.

[78]  F. Gonzalez,et al.  The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα , 2008 .

[79]  C. Ioannides.  Cytochromes P450 : role in the metabolism and toxicity of drugs and other xenobiotics , 2008 .

[80]  Vicki L Dellarco,et al.  Mode of action in relevance of rodent liver tumors to human cancer risk. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[81]  U. Pitkänen,et al.  Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants , 2004, European Journal of Clinical Pharmacology.

[82]  J. Pascussi,et al.  INDUCTION OF CYP 2 C GENES IN HUMAN HEPATOCYTES IN PRIMARY CULTURE , 2001 .

[83]  P. Maurel,et al.  Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[84]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[85]  G. Williams,et al.  Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[86]  B. Diwan,et al.  Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5- dichloropyridyloxy)]benzene in rats at doses that cause maximal induction of CYP2B. , 1996, Carcinogenesis.

[87]  B. Lake.  Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. , 1995, Annual review of pharmacology and toxicology.

[88]  T. K. Baker,et al.  Modulation of gap junctional intercellular communication in rodent, monkey and human hepatocyte by nongenotoxic compounds. , 1995, Progress in clinical and biological research.

[89]  A. Okey.  Enzyme induction in the cytochrome P-450 system. , 1990, Pharmacology & therapeutics.

[90]  J. Reddy,et al.  Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. , 1983, Critical reviews in toxicology.

[91]  Reddy Jk,et al.  Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .

[92]  F. P. Woodford,et al.  Anticonvulsant Drugs and Enzyme Induction , 1976 .

[93]  D. Parke.  The biochemistry of foreign compounds , 1968 .